GNMSF (Genmab AS) 3-Year Revenue Growth Rate : 17.70% (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Genmab AS 3-Year Revenue Growth Rate?

Genmab AS's Revenue per Share for the three months ended in Sep. 2024 was $12.90.

During the past 12 months, Genmab AS's average Revenue per Share Growth Rate was 19.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 17.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 36.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was 38.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Genmab AS was 326.80% per year. The lowest was -20.40% per year. And the median was 34.45% per year.

Competitive Comparison of Genmab AS's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Genmab AS's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab AS's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Genmab AS's 3-Year Revenue Growth Rate falls into.

Genmab AS 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Genmab AS (OTCPK:GNMSF) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Genmab AS 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Genmab AS's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OTCPK:GNMSF) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

GMAB:USA GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.